ACTIVE

OMEGA PHARMA INNOVATION & DEVELOPMENT

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result11,4 M €+16,7 %over 1 year

Revenue16,3 M €-70,4 %over 1 year

Equity240,2 M €+92,7 %over 1 year

Workforce38,2 ETP-11,4 %over 1 year

Identity

Source · BCE/KBO

OMEGA PHARMA INNOVATION & DEVELOPMENT is a Public limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 38,2 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0884.084.724
Incorporation: 09/10/2006
Legal form: Public limited company
Registered office: Gaston Crommenlaan 6 box 606
9050 Gent · FlandreSee on map
Contributed capital: 123 392 195,00 €
Latest accounts: 31/12/2025
Average workforce: 38,2 ETP

Activities (NACE)

72101Research and experimental development on natural sciences and engineering· main 72109Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 72190Other research and experimental development on natural sciences and engineering 73100Advertising

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 19 filings

Trend over 17 financial years

	2025		2023		2022		2021		2020
Income statement
Revenue	16,3 M €	-70.4%	55,2 M €	+12.4%	49,1 M €	+10.0%	44,7 M €	+1.4%	44,1 M €
EBITDA	997 k €	-95.3%	21 M €	+21.1%	17,4 M €	+55.3%	11,2 M €	+106%	-187,3 M €
Operating result	-545,8 k €	-106%	9 M €	+313%	2,2 M €	+146%	-4,8 M €	+97.9%	-227,5 M €
Net result	11,4 M €	+16.7%	9,7 M €	+390%	2 M €	+120%	-9,9 M €	+94.7%	-186,1 M €
Balance sheet
Equity	240,2 M €	+92.7%	124,6 M €	+1.0%	123,4 M €	+1.6%	121,4 M €	-55.8%	274,8 M €
Total assets	246,6 M €	+61.4%	152,8 M €	+4.9%	145,7 M €	+2.6%	141,9 M €	-60.2%	356,7 M €
Cash	7,2 k €	+306%	1,8 k €	0.0%	1,8 k €	0.0%	1,8 k €	0.0%	1,8 k €
Debts	6,4 M €	-77.2%	28 M €	+40.7%	19,9 M €	-0.1%	19,9 M €	-75.2%	80,3 M €
Other
Workforce	38,2 ETP	-11.4%	43,1 ETP	-3.1%	44,5 ETP	-4.7%	46,7 ETP	-0.6%	47,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 38 ended

Active mandates

Jonas Dhaenens

Director · since 22 mai 2026 · until 13 mai 2032

Active

Sonia Hollies

Director · since 29 août 2024 · until 09 mai 2030

Active

Magali Verbraeken

Director · since 23 janvier 2023 · until 22 janvier 2029

Active

Anja van Winsberghe

Director · since 17 mai 2021 · until 22 mai 2026

Active

Ended mandates

Mira De Maeyer

Director · since 01 janvier 2024 · until 31 décembre 2029

Ended

Gianluca Parola

Director · since 29 juillet 2021 · until 01 décembre 2022

Ended

Gianluca Parola

Director · since 29 juillet 2021 · until 13 mai 2027

Ended

Anja van Winsberghe

Director · since 17 mai 2021 · until 13 mai 2027

Ended

Other companies at this address

Gaston Crommenlaan 6 9050 Gent

Company	CBE no.
BRAVX● Active	0834.939.871
LIGHTHOUSE INTELLIGENCE● Active	0676.420.293
Oce-Bio● Active	0442.861.022
omega pharma group● Active	0837.048.632
OMEGA PHARMA INTERNATIONAL● Active	0807.596.363
OMEGA PHARMA TRADING● Active	0417.092.080
Perrigo Belgium● Active	0417.132.860
Perrigo Capital● Active	0430.784.027
Perrigo Europe Invest● Active	0439.658.834
Perrigo Holding● Active	0431.676.229
TM BRAVO4 CIVIEL● Active	0787.232.501
TM BRAVO-4 KOEPEL-EPC● Active	1008.974.796
TM Goedingebrug● Active	1039.143.281
TM Nieuwe Waasmunsterbrug over Durme● Active	1035.016.328

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	07/07/2026	18/06/2025	22/05/2024	25/05/2023	17/06/2022	14/06/2021
General meeting	29/06/2026	20/05/2025	13/05/2024	11/05/2023	12/05/2022	17/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 19 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	29/06/2026	07/07/2026	Dutch	PDF
Full model	31/12/2024	20/05/2025	18/06/2025	Dutch	PDF
Full model	31/12/2023	13/05/2024	22/05/2024	Dutch	PDF
Full model	31/12/2022	11/05/2023	25/05/2023	Dutch	PDF
Full model	31/12/2021	12/05/2022	17/06/2022	Dutch	PDF
Full model	31/12/2020	17/05/2021	14/06/2021	Dutch	PDF
Full model	31/12/2019	14/05/2020	11/06/2020	Dutch	PDF
Full model	31/12/2018	09/05/2019	27/05/2019	Dutch	PDF
Full model	31/12/2017	18/06/2018	22/06/2018	Dutch	PDF
Full model	31/12/2016	29/09/2017	14/11/2017	Dutch	PDF
Full model	31/12/2015	30/06/2016	15/07/2016	Dutch	PDF
Full model	31/12/2014	15/06/2015	19/06/2015	Dutch	PDF
Full model	31/12/2013	16/06/2014	24/06/2014	Dutch	PDF
Full model	31/12/2012	17/06/2013	26/06/2013	Dutch	PDF
Full model	31/12/2011	18/06/2012	16/07/2012	Dutch	PDF
Abridged model	31/12/2010	20/06/2011	28/07/2011	French	PDF
Abridged model	31/03/2010	17/09/2010	30/09/2010	French	PDF
Abridged model	31/03/2009	18/09/2009	30/10/2009	French	PDF
Abridged model	31/03/2008	02/02/2009	14/04/2009	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 38 ended

Active mandates

Jonas Dhaenens

Director · since 22 mai 2026 · until 13 mai 2032

Active

Sonia Hollies

Director · since 29 août 2024 · until 09 mai 2030

Active

Magali Verbraeken

Director · since 23 janvier 2023 · until 22 janvier 2029

Active

Anja van Winsberghe

Director · since 17 mai 2021 · until 22 mai 2026

Active

Ended mandates

Mira De Maeyer

Director · since 01 janvier 2024 · until 31 décembre 2029

Ended

Gianluca Parola

Director · since 29 juillet 2021 · until 01 décembre 2022

Ended

Gianluca Parola

Director · since 29 juillet 2021 · until 13 mai 2027

Ended

Anja van Winsberghe

Director · since 17 mai 2021 · until 13 mai 2027

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates08/06/2026
ONTSLAGEN - BENOEMINGEN
PDF
Mandates22/12/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates15/10/2024
ONTSLAGEN - BENOEMINGEN
PDF
Mandates18/06/2024
ONTSLAGEN - BENOEMINGEN
PDF
Registered office15/03/2024
MAATSCHAPPELIJKE ZETEL
PDF
Mandates07/03/2024
ONTSLAGEN - BENOEMINGEN
PDF
Mandates01/03/2023
ONTSLAGEN - BENOEMINGEN
PDF
Mandates05/01/2023
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

22/05/2026
nominationJonas Dhaenens — bestuurder
2025
Annual accounts 202511,4 M €↑
20/05/2025
nominationBDO Bedrijfsrevisoren BV — commissaris
29/08/2024
nominationSonia Hollies — bestuurder
13/05/2024
reconductionPaul Eelen — commissaris
01/01/2024
nominationMira De Maeyer — bestuurder
2023
Annual accounts 20239,7 M €↑
23/01/2023
nominationMagali Verbraeken — bestuurder
2022
Annual accounts 20222 M €↑
2021
Annual accounts 2021-9,9 M €↑
2020
Annual accounts 2020-186,1 M €↓
2019
Annual accounts 2019-45,5 M €↓
2018
Annual accounts 2018-28,6 M €↓
2017
Annual accounts 2017-7,1 M €↑
2016
Annual accounts 2016-142,5 M €↓
2015
Annual accounts 2015-32,3 M €↓
2014
Annual accounts 20147,7 M €↑
2012
Annual accounts 2012-1,7 M €↓
2011
Annual accounts 2011977,2 k €↑
2011
Name changeOMEGA PHARMA INNOVATION & DEVELOPMENT
2010
Annual accounts 2010742,3 k €↓
2010
Annual accounts 2010803,6 k €↑
2009
Annual accounts 2009160,5 k €↓
2008
Annual accounts 2008589,1 k €
2008
Name changelaboratoires DUHOT
09/10/2006
IncorporationPublic limited company

OMEGA PHARMA INNOVATION & DEVELOPMENT

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline